Search the Newsreel

Moderna Q2 Earnings Loom: Buy or Sell the Stock Ahead of Results?

Moderna (MRNA) is preparing to report its second-quarter 2026 earnings, with analysts expecting a decline in sales but an improvement in the bottom line. The company's earnings surprise history is strong, though its current Earnings ESP and Zacks Rank suggest it's not poised for …

Moderna, Inc. $MRNA Shares Bought by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. significantly increased its stake in Moderna (NASDAQ: MRNA) by 41.3% in the first quarter of 2026, bringing its total holdings to 69,883 shares valued at $3.55 million. Despite this institutional buying, analysts maintain a cautious outlook with a consensus …

Dimensional Fund Advisors LP Buys 343,216 Shares of Moderna, Inc. $MRNA

Dimensional Fund Advisors LP increased its stake in Moderna, Inc. by 19.2% in the first quarter, acquiring an additional 343,216 shares. The firm now owns over 2.1 million shares valued at approximately $108.2 million. Other institutional investors also adjusted their positions, with hedge funds …

Eversept Partners LP Has $8.11 Million Stock Holdings in Moderna, Inc. $MRNA

Eversept Partners LP reduced its stake in Moderna, Inc. by 40.4% during Q1, now holding 159,708 shares valued at $8.11 million. Despite this, other institutional investors adjusted their positions, and insiders sold a significant number of shares. Analysts currently rate Moderna as "Reduce" with …

Renaissance Technologies LLC Acquires 312,800 Shares of Moderna, Inc. $MRNA

Renaissance Technologies LLC increased its holdings in Moderna, Inc. by 55.0% during the first quarter, adding 312,800 shares to own a total of 881,200 shares valued at $44,765,000. Other institutional investors also made significant moves in Moderna stock. The stock is facing a "Reduce" …

(MRNA) as a Liquidity Pulse for Institutional Tactics

This article provides an in-depth analysis of Moderna Inc. (NASDAQ: MRNA) for institutional traders, focusing on liquidity pulses and tactical strategies. It highlights weak near and mid-term sentiment but a strong long-term outlook, with specific AI-generated trading signals, including entry zones, targets, and stop …

Moderna (MRNA) Laps the Stock Market: Here's Why

Moderna (MRNA) stock closed up 2.89% in the latest trading session, outperforming the S&P 500, Dow, and Nasdaq. The biotechnology company is set to report earnings on July 31, 2026, with an anticipated increase in EPS despite a projected decrease in revenue. Analysts are …

After Soaring Nearly 90% Thus Far in 2026, Is Moderna's Stock Still a Buy?

Moderna's stock has rallied significantly in 2026, partly due to positive news on its seasonal influenza vaccine. However, the article argues that the rally is not justified due to an underwhelming pipeline with limited game-changing potential outside of a personalized cancer vaccine, ongoing operating …

Q1 Earnings Highlights: Moderna (NASDAQ:MRNA) Vs The Rest Of The Therapeutics Stocks

This article reviews Q1 earnings for several therapeutics stocks, highlighting Moderna's strong performance with a 260% revenue increase and leading the group in revenue growth. Novavax also exceeded analyst expectations, while United Therapeutics showed the weakest performance. Amgen and Halozyme Therapeutics reported satisfactory quarters, …

Moderna stock stays tied to vaccine demand and cash burn

Moderna's stock remains closely tied to vaccine demand and its significant cash burn, reflecting a business in transition after a sharp decline in revenue from pandemic peaks. The company reported 2025 revenue of $3.0 billion, R&D expenses of $2.7 billion, and a net loss …

Moderna, Inc. Revenue Breakdown – BX:0QF

Moderna, Inc. (0QF) generated 1.54 billion CHF last year, predominantly from its Messenger RNA (mRNA) Medicines segment. This marks a decrease from the previous year's 2.94 billion CHF for the same segment. The United States was the largest contributor to revenue, accounting for 950.53 …

Moderna: A Stock to Watch or a Risky Bet?

This article features a Motley Fool Scoreboard episode discussing Moderna (NASDAQ: MRNA) to help investors gain insights into market trends and potential opportunities. While experts analyze Moderna, the article also highlights other investment recommendations from Motley Fool's Stock Advisor, noting Moderna was not among …

Moderna Inc (MRNA) Institutional Confidence

Moderna Inc (MRNA) has an institutional shareholding score of 7.00, placing it 50th out of 155 in the pharmaceuticals industry. The institutional shareholding proportion recently increased by 3.46% quarter-over-quarter, now standing at 78.90%. Fidelity Management & Research Company LLC, BlackRock Institutional Trust Company, N.A., …

Moderna stock may move 4.2% on July 31 earnings release By Investing.com

Moderna Inc. (MRNA) stock is projected to move 4.2% around its July 31 earnings release, according to options data. Historically, the stock has exceeded its implied move in three of the last eight earnings announcements. Notably, its largest post-earnings move in the past two …

Moderna Inc (MRNA) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Moderna Inc (MRNA), detailing its current earnings forecast score, analyst ratings, and price targets. It includes expected revenue for the next quarter, past and future EPS, and a peer comparison within the Pharmaceuticals industry. The majority of …

Baillie Gifford (MRNA) discloses 18.2M Moderna shares in latest 13G/A

Baillie Gifford & Co has filed Amendment No. 7 to a Schedule 13G/A, reporting its passive ownership in Moderna, Inc. As of June 30, 2026, the firm beneficially owned 18,206,778 shares of Moderna common stock, which represents 4.59% of the outstanding shares. This filing …

Will Moderna (MRNA) Report Negative Earnings Next Week? What You Should Know

Moderna (MRNA) is expected to report a year-over-year increase in earnings on lower revenues for the quarter ended June 2026, with an estimated loss of $1.97 per share. Despite a positive year-over-year change in earnings, the Zacks Earnings ESP for Moderna is -2.41%, combined …

Moderna (MRNA) Stock Looks Above Fair Value After Cancer Trial News

Moderna (MRNA) stock has seen an 84.8% return year-to-date, but its current valuation, with a P/S ratio of 10.2x against a tailored P/S of 2.6x, suggests it is overvalued. Despite progress in its cancer program and flu vaccine, the stock's high price reflects investor …

Moderna (MRNA) Projected to Post Earnings on Friday

Moderna (MRNA) is projected to announce its Q2 2026 earnings before the market opens on Friday, July 31st. Analysts expect a loss of ($2.00) per share on revenue of approximately $103.1 million. The company's prior quarter widely beat revenue estimates but still posted a …

Earnings Preview: What To Expect From Moderna’s Report

Himension Capital Singapore PTE. LTD. Cuts Position in Moderna, Inc. $MRNA

Himension Capital Singapore PTE. LTD. reduced its stake in Moderna, Inc. by 38.8% in Q1, selling 22,390 shares and holding stock worth $1.795 million. Despite this, other institutions like PNC Financial Services Group Inc., Commerzbank Aktiengesellschaft FI, AlTi Global Inc., Meeder Advisory Services Inc., …

Moderna Rabies Vaccine Candidate by Moderna Inc. - mRNA approach in early trials

Moderna Inc. is developing an mRNA-based rabies vaccine candidate, which is currently in early clinical development as a prophylactic. This vaccine uses mRNA technology to trigger an immune response against the rabies virus, potentially offering a more flexible and faster development process compared to …

California Public Employees Retirement System Purchases 149,192 Shares of Moderna, Inc. $MRNA

The California Public Employees Retirement System increased its stake in Moderna, Inc. by 31.1% in the first quarter, purchasing an additional 149,192 shares. Other institutional investors also adjusted their holdings in Moderna, which currently has 75.33% institutional ownership. Analyst ratings for Moderna are mixed, …

Is Moderna (MRNA) Fully Valued As Board Changes And Earnings Near?

Moderna (MRNA) has appointed Michael McDonnell to its Board and Audit Committee amidst fluctuating stock performance and an upcoming earnings report. While the company has seen strong year-to-date gains, its valuation is considered overvalued by analysts, with a consensus price target of $44.25 against …

Moderna (MRNA) Appoints Michael McDonnell To Board As Committee Roles Shift

Moderna has appointed Michael McDonnell to its Board of Directors and Audit Committee, a move aimed at strengthening financial oversight for the company. McDonnell's extensive background in life sciences and as a public company CFO is expected to influence Moderna's approach to capital allocation, …

Moderna Inc. Stock Slides 3.8%, Underperforms Peers

Moderna Inc. (MRNA) saw its stock price decline by 3.8%. This performance indicates that Moderna underperformed compared to its peers within the market. The article provides a brief overview of this stock movement.

Moderna Is Up 109% in 2026. Jim Cramer Just Called It 'Finally Investable Again.' Is the Stock a No-Brainer Buy on Its Recent Pullback?

Moderna's stock has surged 109% in 2026, leading Jim Cramer to declare it "finally investable again." Despite past disappointments and declining coronavirus vaccine demand, the company has made significant progress in its pipeline, cost-cutting, and currently has three approved products, with a flu vaccine …

Goldman Sachs Adjusts Moderna Price Target to $67 From $49, Maintains Neutral Rating

Goldman Sachs has raised its price target for Moderna (MRNA) to $67 from $49, while keeping a Neutral rating on the stock. This adjustment comes amidst various company developments, including Moderna advancing its cancer therapy assessment and recent patent infringement suits against competitors Pfizer …

MRNA Advances Cancer Pipeline With New Immunotherapy Study

Moderna (MRNA) has initiated a phase I study for mRNA-4200, an investigational off-the-shelf, tumor-targeted cancer antigen therapy, in patients with advanced solid tumors. This move aligns with Moderna's long-term strategy to diversify its mRNA platform beyond vaccines into oncology, developing cancer antigen therapies in …

MRNA: Moderna Inc Latest Stock Price, Analysis, News and Trading Ideas

This page provides current stock information for Moderna Inc. (MRNA), including its latest stock price, market capitalization, volume, 52-week high/low, and PE ratio. It also features recent news headlines related to Moderna and discussions about other trending stocks like SPY, SG, and NFLX.

Moderna (MRNA): Buy, Sell, or Hold Post Q1 Earnings?

Despite a 46.4% stock price jump for Moderna (MRNA) over the last six months, partly due to solid quarterly results, StockStory advises against buying the stock. This recommendation is based on a significant decline in revenue and EPS over the past five years, along …

Form 4 Moderna Inc For: 16 July By Investing.com

This article reports a Form 4 filing for Moderna Inc. on July 16, 2026. The piece is brief, stating the filing and including the stock symbol MRNA with a reported -7.51% change. It appears to be an automated news update.

Moderna president Stephen Hoge sells $3.6m in stock

Moderna President Stephen Hoge sold approximately $3.6 million worth of company stock on July 15, 2026, while also acquiring shares through stock options. The transactions were conducted under a Rule 10b5-1 trading plan. This sale occurred as Moderna's stock, MRNA, showed a 132% year-to-date …

Moderna, Inc. (MRNA) president exercises options and sells 53,336 shares under 10b5-1 plan

Moderna President Stephen Hoge exercised stock options to acquire 53,336 shares of common stock at $19.15 per share and subsequently sold all 53,336 shares at $67.60 per share. These transactions, executed on July 15, 2026, were conducted under a pre-arranged Rule 10b5-1 trading plan …

Moderna Inc (MRNA) weekly reversal tests a biotech rebound

The pullback matters because longer weekly returns remain positive, leaving the setup supported but no longer one-way.

ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection?

Arbutus Biopharma (ABUS) stock rose 6% after the company announced new international patent lawsuits, received a significant settlement payment from Moderna, and revealed plans to return up to $230 million to shareholders through share repurchases. The company received approximately $178 million from Moderna as …